Floatz logo

428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
mk-2206
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)P2CCC (50)
Rintatolimod
Triple-Negative Breast Carcinoma
Roswell Park Cancer InstituteP1/2CCC (50)
Utomilumab
Triple-Negative Breast Carcinoma
Laura Huppert, MD, BAP2CCC (50)
Fruquintinib
Triple-Negative Breast Carcinoma
Immunitas TherapeuticsP1/2CCC (49)
Nelitolimod
Triple-Negative Breast Carcinoma
QuantumLeap Healthcare CollaborativeP2CCC (49)
Amiloride
Triple-Negative Breast Carcinoma
Laura Huppert, MD, BAP2CCC (48)
Bcd-236
Triple-Negative Breast Carcinoma
BiocadP2CCC (48)
bi 907828
Triple-Negative Breast Carcinoma
Institut BergoniéP2CCC (48)
bnt327
Triple-Negative Breast Carcinoma
BioNTech SEP2CCC (48)
Desferrioxamine B
Triple-Negative Breast Carcinoma
Sun Yat-sen UniversityP2CCC (48)
Ezabenlimab
Triple-Negative Breast Carcinoma
Institut BergoniéP2CCC (48)
Gedatolisib
Triple-Negative Breast Carcinoma
Kari WisinskiP1/2CCC (48)
Hyaluronidase Zzxf
Triple-Negative Breast Carcinoma
Baylor Breast Care CenterP2CCC (48)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer
Triple-Negative Breast Carcinoma
Cantargia ABP1/2CCC (48)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-48*01 (90.8%) -(Ighd) -Ighj4*01 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg1*01, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-16*01 (89.5%) -Igkj4*01 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa
Triple-Negative Breast Carcinoma
MedSIRP2CCC (48)
Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer
Triple-Negative Breast Carcinoma
QuantumLeap Healthcare CollaborativeP2CCC (48)
Inbrx-106
Triple-Negative Breast Carcinoma
Providence Health & ServicesP2CCC (48)
Jab-2485
Triple-Negative Breast Carcinoma
Jacobio Pharmaceuticals Co., Ltd.P1/2CCC (48)
n17350
Triple-Negative Breast Carcinoma
Onchilles Pharma IncP1/2CCC (48)
Navicixizumab
Triple-Negative Breast Carcinoma
OncXerna Theraputics, Inc.P2CCC (48)
Naxitamab
Triple-Negative Breast Carcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Ociperlimab
Triple-Negative Breast Carcinoma
Novartis PharmaceuticalsP2CCC (48)
Pd-L1 T-Hank
Triple-Negative Breast Carcinoma
ImmunityBio, Inc.P1/2CCC (48)
Relatlimab
Triple-Negative Breast Carcinoma
Yale UniversityP1/2CCC (48)
Resiquimod
Triple-Negative Breast Carcinoma
Institut BergoniéP2CCC (48)
sg001
Triple-Negative Breast Carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.P2CCC (48)
Simvastatin
Triple-Negative Breast Carcinoma
Indonesia UniversityP2CCC (48)
Star0602
Triple-Negative Breast Carcinoma
Marengo Therapeutics, Inc.P1/2CCC (48)
Surufatinib
Triple-Negative Breast Carcinoma
Huihua XiongP1/2CCC (48)
TIL
Triple-Negative Breast Carcinoma
Essen BiotechP1/2CCC (48)
Tocilizumab
Triple-Negative Breast Carcinoma
Kathy MillerP2CCC (48)
177lu-betabart
Triple-Negative Breast Carcinoma
Radiopharm Theranostics, LtdP1/2CC (47)
Bms-936558-01
Triple-Negative Breast Carcinoma
Bristol-Myers SquibbP1/2CC (47)
Cabozantinib
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)P1CC (47)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer
Triple-Negative Breast Carcinoma
Bristol-Myers SquibbP1/2CC (47)
Oncolytic Virus Rp1
Triple-Negative Breast Carcinoma
Institut CurieP1/2CC (47)
Prgn-3007
Triple-Negative Breast Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (47)
Pumitamig
Triple-Negative Breast Carcinoma
Bristol-Myers SquibbP1/2CC (47)
ucb4594
Triple-Negative Breast Carcinoma
Cancer Research UKP1/2CC (47)
Zelenectide Pavedotin
Triple-Negative Breast Carcinoma
BicycleTx LimitedP1/2CC (47)
Dazostinag
Triple-Negative Breast Carcinoma
TakedaP1CC (46)
Dexasone
Triple-Negative Breast Carcinoma
Andrew Hantel, MDP1/2CC (46)
Immunoglobulin G1, Anti-(Human Neuregulin Receptor Her3) (Human Monoclonal U3-1287 Heavy Chain), Disulfide With Human Monoclonal U3-1287 ?-Chain, Dimer
Triple-Negative Breast Carcinoma
QuantumLeap Healthcare CollaborativeP2CC (46)
Lenalidomide
Triple-Negative Breast Carcinoma
Andrew Hantel, MDP1/2CC (46)
Obinutuzumab
Triple-Negative Breast Carcinoma
Simcha IL-18, Inc.P1/2CC (46)
Sitravatinib
Triple-Negative Breast Carcinoma
Xiang ZhangP2CC (46)
Balstilimab
Triple-Negative Breast Carcinoma
Yuan YuanP1/2CC (45)
cts2190 capsules
Triple-Negative Breast Carcinoma
CytosinLab Therapeutics Co., Ltd.P1/2CC (45)
Dual-Target Car-Nk Cells
Triple-Negative Breast Carcinoma
Beijing BiotechP1/2CC (45)
Interferon Alpha-2
Triple-Negative Breast Carcinoma
Roswell Park Cancer InstituteP1/2CC (45)
Showing 201 to 250 of 428 assets
PreviousPage 5 of 9Next